The South Korea Label Free Detection Market was valued at $4.9 Million in 2024 and projected to reach to $5.6 Million by 2029, representing a compound annual growth rate of 2.7%. South Korea's label free detection market is positioned for steady growth as the nation's healthcare sector continues modernizing its diagnostic capabilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea's label free detection market is valued at $4.9 million in 2024, with projections to reach $5.6 million by 2029, representing steady growth in the healthcare diagnostics sector.
The South Korean market is expanding at a CAGR of 2.7%, outpacing many developed economies but reflecting a more conservative adoption rate compared to the global average of 7.7%.
South Korea's advanced healthcare infrastructure is increasingly integrating label free detection technologies to improve diagnostic accuracy and reduce operational costs in clinical laboratories and research institutions.
The modest growth trajectory indicates selective adoption among South Korean healthcare providers, driven by cost-consciousness and the need for non-invasive, real-time detection capabilities in precision medicine applications.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Eurofins demonstrated the use of Biacore SPR and Octet BLI platforms for therapeutic monoclonal antibody potency assessment under quality control and Good Manufacturing Practice (GMP) workflows. The study compared binding performance using reference standards and different analyte concentrations. | Improved potency assessment and batch comparability | Reproducible binding measurements | Supports GMP-compliant biologics quality control |
|
|
Quality Assistance documented the use of SPR-based Biacore technology for adalimumab receptor-binding analysis, pembrolizumab potency testing, and influenza hemagglutinin quantification. These applications support biotherapeutic characterization and analytical quality control. | Accurate affinity and potency assessment | Improved batch comparability | Supports biotherapeutic quality evaluation |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | BIOSENSOR CHIPS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 7.7% from 2024 to 2029 |
| Largest Segment | SURFACE PLASMON RESONANCE (Technology) |
| Market Size Base Year (Billions) | ~USD 0.52 (2024) |
| Revenue Forecast (Billions) | ~USD 0.75 (2029) |
| Segments Covered | Offering, Type, Technology, Application, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| INSPLORION AB | Sweden | Public Company | NPS-P2 hydrogen detector (industrial and energy safety),NPS-P1 metal hydride detection and process monitoring,Remote and distributed optical detection solutions, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, autoimmune, infectious disease),Life-science reagents, antibodies, and assay platforms,Instruments, imaging, software, and services, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (instruments and research consumables),Diagnostics (clinical instruments and consumables), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, cell culture, filtration, fluid management, process chromatography),Lab products and services (lab filtration, weighing, pipettes, microbiological testing, lab water, OEM),Advanced analytics and cell analysis (BLI, cytometry screening, PAT, data analytics, live-cell imaging, SPR), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| WATERS CORPORATION | United States | Public Company | Liquid Chromatography Systems and Columns,Mass Spectrometry Systems,Thermal Analysis, Rheometry, and Calorimetry (TA segment), |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials (mobile device glass, semiconductor optics, radiation shielding, sunglasses), |
| AMETEK, INC. | United States | Public Company | Process, analytical, and industrial instruments (EIG),Aerospace and defense electronics and sensors,Electromechanical and motion products (EMG), |
| HORIBA, LTD. | Japan | Public Company | Mobility, Powertrain & Emissions Testing,Energy & Environment (Water, Process, Energy Analytics),Bio & Healthcare (IVD and Life Science Instrumentation), |
| SPECTRIS | United Kingdom | Private Company | Spectris Scientific (advanced measurement and materials characterization),Spectris Scientific (monitoring solutions for ultra-clean manufacturers),Spectris Dynamics (sensing and data acquisition), |
| SHIMADZU CORPORATION | Japan | Public Company | Analytical and Measuring Instruments,Medical Systems,Vacuum and Industrial Machinery, |
| HITACHI HIGH-TECH CORPORATION | Japan | Private Company | Nano-Technology Solutions (electron/ion microscopes, CD-SEM, dry etch, inspection),Analytical & Medical Solutions (clinical analyzers, chromatography, spectroscopy),Industrial Solutions (industrial infrastructure, energy, control systems), |
| ATTANA AB | Sweden | Public Company | Contract research & virus analytics services,Analytical instruments,In vitro diagnostic tools & related solutions, |
| BRUKER | United States | Public Company | BSI BioSpin (NMR, EPR, preclinical imaging),BSI CALID (mass spectrometry, molecular diagnostics, automation),BSI Nano (X-ray, AFM, electron microscopy tools, nanometrology), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research & Bioprocess, |
Insplorion AB is a public company founded in 2010 and based in Sweden with 8 employees.
Revvity, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees.
Danaher Corporation is a public company founded in 1969 and based in the United States with 59,000 employees.
Sartorius AG is a public company founded in 1870 and based in Germany with 14,242 employees.
Agilent Technologies, Inc. is a public company founded in 1999 and based in the United States with 18,000 employees.
Waters Corporation is a public company founded in 1958 and based in the United States with 7,900 employees.
Corning Incorporated is a public company founded in 1851 and based in the United States with 67,200 employees.
AMETEK, Inc. is a public company founded in 1930 and based in the United States with 22,500 employees.
Horiba, Ltd. is a public company founded in 1945 and based in Japan with 9,101 employees.
Spectris is a private company founded in 1986 and based in the United Kingdom with 7,400 employees.
Shimadzu Corporation is a public company founded in 1875 and based in Japan with 14,649 employees.
Hitachi High-Tech Corporation is a private company founded in 1947 and based in Japan with 11,482 employees.
Attana AB is a public company founded in 2002 and based in Sweden with 6 employees.
Bruker is a public company founded in 1960 and based in the United States with 11,085 employees.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 and based in the United States with 7,450 employees.
South Korea's label free detection market is valued at $4.9 million in 2024.
South Korea's label free detection market is projected to reach $5.6 million by 2029.
South Korea's label free detection market is growing at a compound annual growth rate of 2.7% from 2024 to 2029.
South Korea's primary applications include clinical diagnostics, pharmaceutical research, and biomarker discovery in healthcare and life sciences sectors.
South Korea's 2.7% CAGR is lower than the global 7.7% CAGR, reflecting a more mature and established market with steady incremental growth.
This study used secondary sources, directories, and databases to identify and collect information for analyzing the global label free detection market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the label free detection market. The secondary sources used for this study include World Health Organization (WHO), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), US Food and Drug Administration (US FDA), International Molecular Exchange Consortium (IMEx), Biomolecular Interaction Network Database, Nature (Journal), Genome Medicine, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), and Pharmaceutical Research and Manufacturers of America (PhRMA), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations, among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the label free detection market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
The label free detection market focuses on label free detection offerings (instruments, consumables, and software & services) used for analyzing molecular interactions and cellular responses without fluorescent, radioactive, or enzymatic labels. These technologies enable real-time measurement of binding kinetics, affinity, molecular stability, and cellular activity. Label free detection products and services are widely used in drug discovery, biologics development, screening, and life sciences research.
The report provides a comprehensive analysis of the label free detection market, covering a wide range of offerings, including instruments, consumables, and software & services.
Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
Company Information
Full forecast, segment splits, and company analysis for all Label Free Detection Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report